Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18

Section 33

Labelling

Cite as Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18, s. 33 · current to July 24, 2025 · regulation last amended February 27, 2022

Statute Watch

Get an alert when a bill in Parliament would change this section, and every time it moves.

The text

(1) A person must not import or sell a COVID-19 drug for which a COVID-19 drug authorization has been issued or conduct a clinical trial in respect of such a drug unless the drug has a label that sets out the following information: (a) a statement indicating that the drug is an investigational drug to be used only by a qualified investigator; (b) the name, number or identifying mark of the drug; (c) the expiration date of the drug; (d) the recommended storage conditions for the drug; (e) the lot number of the drug; (f) the name and contact information of the holder of the authorization; and (g) the protocol code or identification. (2) The information required by subsection (1) to be set out on the label must be in English and in French.
Read the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations on the Justice Laws Website ↗

Made under Food and Drugs Act, R.S.C. 1985, c. F-27; Patent Act, R.S.C. 1985, c. P-4.

Bills in Parliament that would change this section 0

No bill we hold would amend or repeal this section.